P2D Bioscience is strucured around developiment of treatments for central nervous system (CNS) inflammatory disorders such as Frontotemporal Dementia (FTD) and Alzheimer's disease (AD). Utilizing a targeted phenotypic screening approach and transgenic preclinical models of neurodegenerative diseases in order to accelerate the drug development process, P2D's goal to advance a product candidate through preclinical efficacy testing, GLP-safety studies and early clinical safety and clinical proof-of-concept studies then seek partners to complete the clinical development and commercialization process. The company's pipeline of drug candidates are 1) orally and centrally active isoindoline TNF? inhibitors for the treatment FTD and AD and 2) benztropine-analog DAT inhibitors for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
